High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Tumor Biology

• Publication date

  2016-06-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s13277-016-5075-1PMID 27271990
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Detection of Core2 β-1,6-N-Acetylglucosaminyltransferase in Post-Digital Rectal Examination Urine Is a Reliable Indicator for Extracapsular Extension of Prostate Cancer

  2015cited by this paper
• Transcriptional regulation of the apolipoprotein F (ApoF) gene by ETS and C/EBPα in hepatoma cells.

  2015cited by this paper
• Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer

  2015cited by this paper
• Increased expression of GCNT1 is associated with altered O‐glycosylation of PSA, PAP, and MUC1 in human prostate cancers

  2014cited by this paper
• Best Practices Recommendations in the Application of Immunohistochemistry in Urologic Pathology: Report From the International Society of Urological Pathology Consensus Conference

  2014cited by this paper
• Best Practices Recommendations in the Application of Immunohistochemistry in the Prostate: Report From the International Society of Urologic Pathology Consensus Conference

  2014cited by this paper
• ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease.

  2013cited by this paper
• ERG Protein Expression Is of Limited Prognostic Value in Men with Localized Prostate Cancer

  2013cited by this paper
• Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma

  2013cited by this paper
• ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer

  2012cited by this paper
• ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality.

  2012cited by this paper
• ERG gene rearrangements are common in prostatic small cell carcinomas

  2011cited by this paper
• TMPRSS2/ERG Promotes Epithelial to Mesenchymal Transition through the ZEB1/ZEB2 Axis in a Prostate Cancer Model

  2011cited by this paper
• ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy

  2011cited by this paper
• The Utility of ERG/P63 Double Immunohistochemical Staining in the Diagnosis of Limited Cancer in Prostate Needle Biopsies

  2011cited by this paper
• Immunohistochemistry for ERG Expression as a Surrogate for TMPRSS2-ERG Fusion Detection in Prostatic Adenocarcinomas

  2011cited by this paper
• Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice

  2011cited by this paper
• ERG Transcription Factor as an Immunohistochemical Marker for Vascular Endothelial Tumors and Prostatic Carcinoma

  2011cited by this paper
• Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone

  2011cited by this paper
• ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

  2010cited by this paper
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010cited by this paper
• Comparison of the diagnostic value of fatty acid synthase (FASN) with alpha‐methylacyl‐CoA racemase (AMACR) as prostatic cancer tissue marker

  2010cited by this paper
• Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

  2010cited by this paper
• Antibody-based detection of ERG rearrangement-positive prostate cancer.

  2010cited by this paper
• Integrative genomic profiling of human prostate cancer.

  2010influential reference
• α‐Methylacyl‐CoA racemase (AMACR) in fine‐needle aspiration specimens of prostate lesions

  2009cited by this paper
• Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens.

  2009cited by this paper
• Molecular cloning and preliminary analysis of the human α-methylacyl-CoA racemase promoter

  2009cited by this paper
• Conversion of prostate cancer from hormone independency to dependency due to AMACR inhibition: involvement of increased AR expression and decreased IGF1 expression.

  2009cited by this paper
• TMPRSS2-ERG fusion is frequently observed in gleason pattern 3 prostate cancer in a Canadian cohort

  2009cited by this paper
• TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas

  2009cited by this paper
• Molecular cloning and preliminary analysis of the human alpha-methylacyl-CoA racemase promoter.

  2009cited by this paper
• AMACR expression in colorectal cancer is associated with left-sided tumor localization

  2008cited by this paper
• TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis

  2008cited by this paper
• α‐Methylacyl‐CoA racemase – an ‘obscure’ metabolic enzyme takes centre stage

  2008cited by this paper
• Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer

  2008cited by this paper
• Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer

  2007cited by this paper
• TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

  2007cited by this paper
• Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers

  2007cited by this paper
• Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues

  2007cited by this paper
• Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer

  2007cited by this paper
• TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

  2007cited by this paper
• TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.

  2006cited by this paper
• Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression

  2006cited by this paper
• Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.

  2006cited by this paper
• TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions.

  2006cited by this paper
• Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

  2006cited by this paper
• The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

  2005cited by this paper
• Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl‐CoA racemase (AMACR) in the work‐up of prostate cancer

  2005cited by this paper
• A Nonclassic CCAAT Enhancer Element Binding Protein Binding Site Contributes to α-Methylacyl-CoA Racemase Expression in Prostate Cancer

  2005cited by this paper
• Alpha‐methylacyl‐CoA racemase (AMACR) expression in normal prostatic glands and high‐grade prostatic intraepithelial neoplasia (HGPIN): Association with diagnosis of prostate cancer

  2005cited by this paper
• Decreased α-Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death

  2005cited by this paper
• Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.

  2004cited by this paper
• Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer.

  2003cited by this paper
• Branched fatty acids in dairy and beef products markedly enhance alpha-methylacyl-CoA racemase expression in prostate cancer cells in vitro.

  2003cited by this paper
• Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.

  2002cited by this paper
• α-methylacyl-CoA racemase: A new molecular marker for prostate cancer

  2002cited by this paper
• Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.

  2002cited by this paper
• alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.

  2002cited by this paper
• Subcellular localization and physiological role of alpha-methylacyl-CoA racemase.

  2000cited by this paper
• A role for both Ets and C/EBP transcription factors and mRNA stabilization in the MAPK-dependent increase in p21 (Cip-1/WAF1/mda6) protein levels in primary hepatocytes.

  2000cited by this paper
• Purification and characterization of an alpha-methylacyl-CoA racemase from human liver.

  1995cited by this paper

• AMACR is a highly sensitive and specific immunohistochemical marker for diagnosing prostate cancer on biopsy: a systematic review and meta-analysis

  2025cites this paper
• Uncovering genes driving developmental stage progression in prostate cancer through spatial transcriptomics

  2025cites this paper
• Selective autophagy in cancer: mechanisms, therapeutic implications, and future perspectives

  2024cites this paper
• Peroxisomes and PPARs: Emerging role as master regulators of cancer metabolism

  2024cites this paper
• Immunohistochemical Expression of Alpha-Methyl-Coa (AMACR) and ERG in Prostatic Adenocarcinoma and Prostatic Hyperplasia: A Comparative Study

  2023influential citation
• Advances in measuring cancer cell metabolism with subcellular resolution

  2022cites this paper
• Correlation of NTRK1 Downregulation with Low Levels of Tumor-Infiltrating Immune Cells and Poor Prognosis of Prostate Cancer Revealed by Gene Network Analysis

  2022influential citation
• Nanotechnological Approaches in Prostate Cancer Therapy: Integration of engineering and biology

  2022cites this paper
• Autophagy and organelle homeostasis in cancer.

  2021cites this paper
• Peroxisome Metabolism in Cancer

  2020cites this paper
• Phase-Regulated Sensing Mechanism of MoS2 Based Nanohybrids toward Point-of-Care Prostate Cancer Diagnosis.

  2020cites this paper
• Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers

  2019cites this paper
• Circulating mRNA Signature as a Marker for High-Risk Prostate Cancer.

  2019cites this paper
• Transcriptomic analysis of prostate cancer progression

  2018cites this paper
• T2E (TMPRSS2-ERG) fusion transcripts are associated with higher levels of AMACR mRNA and a subsequent prostate cancer diagnosis in patients with atypical small acinar proliferation.

  2018cites this paper
• Peroxisomes and cancer: The role of a metabolic specialist in a disease of aberrant metabolism.

  2018cites this paper
• Proteomic Breast Cancer Classification

  2018cites this paper
• RNA‐based markers in biopsy cores with atypical small acinar proliferation: Predictive effect of T2E fusion positivity and MMP‐2 upregulation for a subsequent prostate cancer diagnosis

  2018cites this paper
• Metabolic Reprogramming and Oncogenesis: One Hallmark, Many Organelles.

  2017cites this paper
• Ekspresi alpha methylacyl co-a racemase (amacr) pada adenokarsinoma prostat dan high grade prostatic intraepithelial neoplasia (hgpin)

  2017cites this paper
• Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.

  2017cites this paper
• Signaling networks in TMPRSS2-ERG positive prostate cancers: Do we need a Pied Piper or sharpshooter to deal with "at large" fused oncoprotein.

  2017cites this paper
• Emerging proteomics biomarkers and prostate cancer burden in Africa

  2017cites this paper
• A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy

  2016cites this paper